Table 3.
Primary and secondary outcomes according to treatment in 278 children with confirmed APN on DMSA at entry according to allocation to new treatment (oral co-amoxiclav) or standard treatment (parenteral ceftriaxone followed by oral co-amoxiclav); exploratory subgroup analysis. Figures are means (SD) unless specified otherwise
| Parameter | New treatment (n=135) | Standard treatment (n=143) | Mean difference (95% CI) |
|---|---|---|---|
| Short term outcomes | |||
| Time to defervescence (hours) | 39.5 (20.1) (n=134) | 37.2 (21.8) (n=141) | 2.3 (−2.7 to 7.3) |
| White cell count (×109/l)* | 10.0 (3.7) (n=127) | 9.6 (3.5) (n=138) | 0.4 (−0.5 to 1.3) |
| Neutrophils (×109/l)* | 3.4 (2.4) (n=114) | 3.1 (2.1) (n=122) | 0.3 (−0.3 to 0.9) |
| Erythrocyte sedimentation rate (mm in first hour)* | 64.1 (30.8) (n=92) | 59.5 (27.6) (n=102) | 4.6 (−3.7 to 12.8) |
| C reactive protein (mg/l)*† | 10.2 (11.9) (n=128) | 10.9 (19.3) (n=141) | 0.7 (−4.2 to 3.1) |
| Primary outcome | |||
| Scar on renal scan at 12 months | 26/96 (27.8%) | 33/100 (33.0%) | −5.8% (−18.7% to 6.9%) |
*Parameters obtained 72 hours after initiation of antibiotic therapy.
†Ratio between obtained value and upper limit of normal reference values for each laboratory.